Hedge fund claims Savient's bankrupt after failed Krystexxa launch

Savient ($SVNT) is grappling with a high-profile lawsuit from the hedge fund Tang Capital, which accuses the company of bungling the launch of its gout drug Krystexxa--and contends that Savient is essentially insolvent. Report